Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study.

Rizzo M, Chandalia M, Patti AM, Di Bartolo V, Rizvi AA, Montalto G, Abate N

Cardiovascular diabetology22 Feb 2014Cited by 95 (Europe PMC)

PMID24559258PMCIDPMC3948058DOI10.1186/1475-2840-13-49PepBankPUB-24559258

Summary

BackgroundLiraglutide, a long-acting glucagon-like peptide-1 (GLP-1) analog, has several non- glycemic properties, but its effect on carotid intima-media thickness (IMT), a recognized marker of subclinical atherosclerosis, is still unknown.MethodsA prospective study of 8 months duration in 64 patients with type-2 diabetes and no prior history of coronary artery disease evaluated whether adding liraglutide to metformin affects carotid IMT, measured by color doppler ultrasound.ResultsAfter 8 months, fasting glucose decreased by 2.1 mmol/l and HbA1c by 1.9% (p < 0.01 for all). Liraglutide reduced total-cholesterol and triglycerides by 10%, and LDL-cholesterol by 19%, whereas HDL-cholesterol increased by 18% (p < 0.01 for all lipid changes). Carotid IMT decreased from 1.19 ± 0.47 to 0.94 ± 0.21 mm (p < 0.01). Yet, changes in carotid IMT did not correlate with changes in any other variable studied.ConclusionsLiraglutide decreases carotid IMT after 8 months treatment independently of its effect on plasma glucose and lipids concentrations.Trial registrationClinicalTrials.gov: NCT01715428.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In adults with type 2 diabetes, adding liraglutide to metformin for 8 months decreased fasting glucose by 2.1 mmol/l.
In plain wordsIn adults with type 2 diabetes, fasting blood sugar fell after 8 months of liraglutide added to metformin.
Peptide
Liraglutide
Outcome
DecreaseFasting glucose change
Study
n = 64
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 8 monthsAs given in this study (human).
Measurements
Fasting glucose change
−2.1 mmol/l
8 months
Source sentences
Summary
After 8 months, fasting glucose decreased by 2.1 mmol/l and HbA1c by 1.9% (p < 0.01 for all).
1 context sentence(design, population, supporting numbers)
Summary · context
A prospective study of 8 months duration in 64 patients with type-2 diabetes and no prior history of coronary artery disease evaluated whether adding liraglutide to metformin affects carotid IMT, measured by color doppler ultrasound.
Show in the study text Report a problemFND-2455925801
02HumanNon-randomized trialEfficacy outcome
In adults with type 2 diabetes, adding liraglutide to metformin for 8 months decreased HbA1c by 1.9%.
In plain wordsIn adults with type 2 diabetes, HbA1c fell after 8 months of liraglutide added to metformin.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change
Study
n = 64
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 8 monthsAs given in this study (human).
Measurements
HbA1c change
−1.9%
8 months
Source sentences
Summary
After 8 months, fasting glucose decreased by 2.1 mmol/l and HbA1c by 1.9% (p < 0.01 for all).
1 context sentence(design, population, supporting numbers)
Summary · context
A prospective study of 8 months duration in 64 patients with type-2 diabetes and no prior history of coronary artery disease evaluated whether adding liraglutide to metformin affects carotid IMT, measured by color doppler ultrasound.
Show in the study text Report a problemFND-2455925802
03HumanNon-randomized trialEfficacy outcome
In adults with type 2 diabetes, liraglutide reduced total cholesterol by 10%.
In plain wordsIn adults with type 2 diabetes, total cholesterol fell after 8 months of liraglutide added to metformin.
Peptide
Liraglutide
Outcome
DecreaseTotal cholesterol change
Study
n = 64
Comparator
Baseline
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · 8 monthsAs given in this study (human).
Measurements
Total cholesterol change
−10%
8 months
Source sentences
Summary
Liraglutide reduced total-cholesterol and triglycerides by 10%, and LDL-cholesterol by 19%, whereas HDL-cholesterol increased by 18% (p < 0.01 for all lipid changes).
1 context sentence(design, population, supporting numbers)
Summary · context
A prospective study of 8 months duration in 64 patients with type-2 diabetes and no prior history of coronary artery disease evaluated whether adding liraglutide to metformin affects carotid IMT, measured by color doppler ultrasound.
Show in the study text Report a problemFND-2455925803
04HumanNon-randomized trialEfficacy outcome
In adults with type 2 diabetes, liraglutide reduced triglycerides by 10%.
In plain wordsIn adults with type 2 diabetes, triglycerides fell after 8 months of liraglutide added to metformin.
Peptide
Liraglutide
Outcome
DecreaseTriglycerides change
Study
n = 64
Comparator
Baseline
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · 8 monthsAs given in this study (human).
Measurements
Triglycerides change
−10%
8 months
Source sentences
Summary
Liraglutide reduced total-cholesterol and triglycerides by 10%, and LDL-cholesterol by 19%, whereas HDL-cholesterol increased by 18% (p < 0.01 for all lipid changes).
1 context sentence(design, population, supporting numbers)
Summary · context
A prospective study of 8 months duration in 64 patients with type-2 diabetes and no prior history of coronary artery disease evaluated whether adding liraglutide to metformin affects carotid IMT, measured by color doppler ultrasound.
Show in the study text Report a problemFND-2455925804
05HumanNon-randomized trialEfficacy outcome
In adults with type 2 diabetes, liraglutide reduced LDL-cholesterol by 19%.
In plain wordsIn adults with type 2 diabetes, LDL cholesterol fell after 8 months of liraglutide added to metformin.
Peptide
Liraglutide
Outcome
DecreaseLDL-cholesterol change
Study
n = 64
Comparator
Baseline
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · 8 monthsAs given in this study (human).
Measurements
LDL-cholesterol change
−19%
8 months
Source sentences
Summary
Liraglutide reduced total-cholesterol and triglycerides by 10%, and LDL-cholesterol by 19%, whereas HDL-cholesterol increased by 18% (p < 0.01 for all lipid changes).
1 context sentence(design, population, supporting numbers)
Summary · context
A prospective study of 8 months duration in 64 patients with type-2 diabetes and no prior history of coronary artery disease evaluated whether adding liraglutide to metformin affects carotid IMT, measured by color doppler ultrasound.
Show in the study text Report a problemFND-2455925805
06HumanNon-randomized trialEfficacy outcome
In adults with type 2 diabetes, liraglutide increased HDL-cholesterol by 18%.
In plain wordsIn adults with type 2 diabetes, HDL cholesterol rose after 8 months of liraglutide added to metformin.
Peptide
Liraglutide
Outcome
IncreaseHDL-cholesterol change
Study
n = 64
Comparator
Baseline
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · 8 monthsAs given in this study (human).
Measurements
HDL-cholesterol change
18%
8 months
Source sentences
Summary
Liraglutide reduced total-cholesterol and triglycerides by 10%, and LDL-cholesterol by 19%, whereas HDL-cholesterol increased by 18% (p < 0.01 for all lipid changes).
1 context sentence(design, population, supporting numbers)
Summary · context
A prospective study of 8 months duration in 64 patients with type-2 diabetes and no prior history of coronary artery disease evaluated whether adding liraglutide to metformin affects carotid IMT, measured by color doppler ultrasound.
Show in the study text Report a problemFND-2455925806
07HumanNon-randomized trialEfficacy outcome
In adults with type 2 diabetes, carotid intima-media thickness decreased from 1.19 to 0.94 mm after 8 months of liraglutide added to metformin.
In plain wordsIn adults with type 2 diabetes, the thickness of the carotid artery wall fell after 8 months of liraglutide added to metformin.
Peptide
Liraglutide
Outcome
DecreaseCarotid intima-media thickness
Study
n = 64
Comparator
Baseline
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated · 8 monthsAs given in this study (human).
Measurements
Carotid IMT
1.19 mm
baseline
Carotid IMT
0.94 mm
8 months
Source sentences
Summary
Carotid IMT decreased from 1.19 ± 0.47 to 0.94 ± 0.21 mm (p < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
A prospective study of 8 months duration in 64 patients with type-2 diabetes and no prior history of coronary artery disease evaluated whether adding liraglutide to metformin affects carotid IMT, measured by color doppler ultrasound.
Show in the study text Report a problemFND-2455925807
08HumanNon-randomized trialMechanism
In adults with type 2 diabetes on liraglutide, changes in carotid IMT did not correlate with changes in any other variable studied.
In plain wordsIn adults with type 2 diabetes on liraglutide, the change in artery wall thickness was not linked to changes in the other measures studied.
Peptide
Liraglutide
Outcome
No significant changeCorrelation of IMT change with other variables
Study
n = 64
Comparator
Baseline
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated · 8 monthsAs given in this study (human).
Source sentences
Summary
Yet, changes in carotid IMT did not correlate with changes in any other variable studied.
1 context sentence(design, population, supporting numbers)
Summary · context
A prospective study of 8 months duration in 64 patients with type-2 diabetes and no prior history of coronary artery disease evaluated whether adding liraglutide to metformin affects carotid IMT, measured by color doppler ultrasound.
Show in the study text Report a problemFND-2455925808

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT01715428

Liraglutide and Cardio-Metabolic Risk Markers

University of Palermon = 300Jun 2012 to Dec 2015

Type-2 Diabetes

Trial page ClinicalTrials.govUpdated 22 Nov 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.